Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Space Exits: Bankruptcy Traffic Could Accelerate

This article was originally published in The Tan Sheet

Executive Summary

Gaspari Nutrition, acquired by Allegro Nutrition, sought Chapter 11 protection after its debt load outstripped its revenue outlook. Natrol threw in the towel and filed after federal judges consolidated multiple class action claims accusing the firm of false advertising for its joint relief products.

You may also be interested in...



Class Action Feeding Frenzy Could Chill On Legislation, Judicial Shift

Food and supplement class action complaints could be slowed by legislation in Congress and by judges potentially de-emphasizing reliance on FDA interpretation of statutes, say lawyers during FDLI conference discussion.

Atkins Moves From Private Equity Portfolio To Simply Good Foods Brand

Roark Capital, with properties across the consumer goods and services spectrum, sells Atkins Nutritionals to Conyers Park Acquisition, which will merge with Atkins to form Simply Good Foods and pay Roark total consideration of $730.1m

$25 Million ‘Pure Fiction’ In Natrol Price Tag Made Real

Natrol owner Aurobindo asks a bankruptcy court for an order before previous owner Plethico Pharmaceuticals agrees to pay close to the price of a phantom engineering contract Plethico claimed as a debt. Aurobindo alleged Plethico sold Natrol to prevent creditors from uncovering the sham.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel